Table 1.

Demographics and baseline characteristics

Characteristics	All patients (n=37)
Age, years, median (range)	52 (35–69)
<65	33 (89.2)
≥65	4 (10.8)
ECOG PS
0	3 (8.1)
1	33 (89.2)
Tumor type
Ovarian carcinoma	33 (89.2)
Fallopian tube carcinoma	4 (10.8)
FIGO stage at first diagnosis
I	2 (5.4)
II	6 (16.2)
III	24 (64.9)
IV	5 (13.5)
Location of metastases
Lymph node	29 (78.4)
Peritoneum	21 (56.8)
Liver	13 (35.1)
Spleen	7 (18.9)
Abdominal cavity	6 (16.2)
Lung	5 (13.5)
Number of lines of prior systemic therapy
1	4 (10.8)
2	11 (29.7)
3	10 (27.0)
4	6 (16.2)
≥5	6 (16.2)
Platinum resistant status*
Primary platinum resistant	11 (29.7)
Secondary platinum resistant	15 (40.5)
Primary platinum refractory	11 (29.7)
Previous bevacizumab use	6 (18.2)
Histologic type
Serous adenocarcinoma
High‐grade	22 (59.5)
Low-grade	1 (2.7)
Unknown	5 (13.5)
Endometrioid carcinoma	1 (2.7)
Undifferentiated carcinoma	1 (2.7)
Other epithelial ovarian cancer
High-grade adenocarcinoma	5 (13.5)
Adenocarcinoma (not otherwise specified)	2 (5.4)
PD-L1 expression †, n (%)
PD-L1 CPS≥1	8 (21.6)
PD-L1 CPS<1	11 (29.7)
Unknown	18 (48.6)

Data are n (%) unless otherwise indicated.

*Patients were categorized as primary platinum resistance (disease progression occurring ≥2 months and <6 months after completing first-line platinum therapy), secondary platinum resistance (progression ≥6 months after completing first-line platinum-based chemotherapy but <6 months after completing second-line or later-line platinum-based chemotherapy) and primary platinum refractory (progression <2 months or no response during the first-line platinum-based chemotherapy).

†Mandatory fresh biopsy or archival tissue for PD-L1 expression was not requested at enrollment.

CPS, Combined Positive Score; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; PD-L1, programmed death-ligand 1.